SUPN News and Press, Supernus Pharmaceuticals Inc. From 09/01/23

2023-09-01 10:47:51 ET The European Medicines Agency’s safety committee has recommended that pregnant women avoid using products containing topiramate due to concerns that it may cause neurodevelopmental disorders in children exposed to the drug while in the womb. Topiramate is a...

ROCKVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Super...

ROCKVILLE, Md., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Bethany L. Sensenig has joined the Super...

2023-08-08 22:31:15 ET Supernus Pharmaceuticals, Inc. (SUPN) Q2 2023 Earnings Conference Call August 08, 2023 04:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants Andrew Tsai - ...

2023-08-08 16:33:58 ET Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q2 GAAP EPS of -$0.02 beats by $0.21 . Revenue of $135.6M (-20.3% Y/Y) misses by $8.06M . FY23 Total revenues to be $580M - $620M, vs. $609.65M consensus. For further details ...

Qelbree ® net product sales growth of 179% and 193% in the first three months and first six months of 2023, respectively, compared to the same periods in 2022 $31.0 million and $56.8 million of net product sales in the first three months and first six months of 2023, respectively ...

ROCKVILLE, Md., July 24, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial ...

2023-06-12 11:59:19 ET Summary Supernus Pharmaceuticals faces declining revenues from its long-time top seller Trokendi XR due to generic competition. Despite Trokendi's struggles, Supernus reported a slim increase in aggregate quarterly revenues, with stagnant revenue guidance fo...

2023-06-10 07:40:00 ET Supernus Pharmaceuticals ' (NASDAQ: SUPN) stock price is up 24% over the last 12 months, suggesting investors are still keen on buying it despite its high valuation and some stiff pressure it's getting on its revenue. What could be driving stock traders to bid...

2023-05-09 21:43:08 ET Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Results Conference Call May 09, 2023 04:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants Andrew Tsai - Jeff...